Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Avacopan Noninferior to Prednisone for ANCA - Associated Vasculitis
Avacopan noninferior to prednisone taper for remission at week 26, superior to prednisone taper for sustained remission at week 52 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 18, 2021 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Nephrology, Oncology, Pharmacy, Rheumatology, Journal, Source Type: news

Avacopan Noninferior to Prednisone for ANCA-Associated Vasculitis
THURSDAY, Feb. 18, 2021 -- Avacopan is noninferior, but not superior, to prednisone with respect to remission at week 26 for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, according to a study published in the Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 18, 2021 Category: Pharmaceuticals Source Type: news

New Steroid Dosing Regimen for Myasthenia Gravis New Steroid Dosing Regimen for Myasthenia Gravis
The use of a new rapid tapering regimen resulted in a lower cumulative dose of prednisone with similar clinical outcomes in a new randomized study.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 16, 2021 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news

Strides Pharma receives USFDA approval for Prednisone tablets
Strides Pharma Global Pte Limited, Singapore, has received approval for Prednisone tablets USP in the strengths of 10 mg and 20 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Strides Pharma Science gets USFDA nod for Prednisone tablets
Strides Pharma Science Ltd on Monday said it has received approval from the US health regulator for its generic version of Prednisone tablets, prescribed for a variety of conditions, including allergies, respiratory illness and arthritis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Proposed RA Guidelines: Maximize Methotrexate Before Switching Proposed RA Guidelines: Maximize Methotrexate Before Switching
Use methotrexate aggressively before switching to a biologic or JAK inhibitor, authors propose in guidelines, updated from 2015, for rheumatoid arthritis. They also urge moving away from prednisone.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 9, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Started Early, Drug Combo Eases Fatigue of Rheumatoid Arthritis: Study
FRIDAY, June 26, 2020 -- Early and intensive treatment with methotrexate and prednisone can ease fatigue in people with rheumatoid arthritis (RA), according to a new study. RA causes chronically inflamed joints and that inflammation can lead to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 26, 2020 Category: General Medicine Source Type: news

COVID - 19 Hospitalization Up With Prednisone in Rheumatic Disease
No correlation seen for DMARD alone or in combination with biologics, Janus Kinase inhibitors, NSAIDs (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 23, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

COVID-19 Hospitalization Up With Prednisone in Rheumatic Disease
TUESDAY, June 23, 2020 -- For patients with rheumatic disease with COVID-19, glucocorticoids are associated with increased odds of hospitalization, according to a study published in the July issue of the Annals of Rheumatic Diseases. Milena... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2020 Category: Pharmaceuticals Source Type: news

What Does Prednisone Do to Your Body?
Title: What Does Prednisone Do to Your Body?Category: MedicationsCreated: 6/23/2020 12:00:00 AMLast Editorial Review: 6/23/2020 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 23, 2020 Category: Drugs & Pharmacology Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
Basel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumours had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overal...
Source: Roche Investor Update - June 19, 2020 Category: Pharmaceuticals Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TNF Inhibitors May Dampen COVID-19 Severity TNF Inhibitors May Dampen COVID-19 Severity
Patients on a TNF inhibitor when contracting COVID-19 were less likely to require hospitalization. Conversely, patients on ≥ 10 mg of prednisone daily when infected were more likely to be hospitalized.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - May 21, 2020 Category: Rheumatology Tags: Rheumatology News Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Anifrolumab Benefits Seen in Second Lupus RCT Analysis Anifrolumab Benefits Seen in Second Lupus RCT Analysis
The monoclonal anifrolumab improved BICLA responses, reduced use of prednisone, and improved skin disease in patients with SLE, particularly those with high type 1 interferon gene signatures.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 23, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news

University of Cincinnati finds new option for liver transplant patients
(University of Cincinnati) Budesonide, a drug commonly used to treat Crohn's Disease, may offer fewer side effects and work at least as well as prednisone as an anti-organ rejection medication in liver transplant patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2019 Category: International Medicine & Public Health Source Type: news

Study Finds Those With Asthma Should Avoid High-Dose Steroids
BOSTON (CBS)- A warning for people with asthma.  A new study finds some asthmatics are taking harmful doses of steroids that could be putting their health at risk. Oral steroids, like prednisone, reduce inflammation and are often used to ease the breathing of patients in the throes of an asthma attack.  But prolonged or excessive doses can put patients at higher risk for diabetes, osteoporosis and hormonal abnormalities. Researchers in the Netherlands studied more than two thousand patients with severe asthma who were on high doses of inhaled steroids and found that almost a third of them were also taking harmful...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Asthma Dr. Mallika Marshall Health Watch oral steroids Source Type: news

Can Metformin Improve Outcomes When Added to Chemotherapy in Prostate Cancer?
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

‘More Is Not Better’ in Metastatic Castration-Resistant Prostate Cancer
This study compared combination therapy with enzalutamide, abiraterone, and prednisone vs enzalutamide alone in men with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 1, 2019 Category: Cancer & Oncology Authors: Lauren M. Dembeck Source Type: news

Medical News Today: Is it safe to drink alcohol while taking prednisone?
Whether a person can drink alcohol while taking prednisone depends on a range of factors, including the length of the treatment, the dosage, and how much alcohol they drink. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 7, 2019 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Final LATITUDE Results Confirm Previous Findings for High-Risk Prostate Cancer
Final results of LATITUDE confirm the beneft of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

prednisone (Prednisone Intensol, Rayos) Corticosteroid
Title: prednisone (Prednisone Intensol, Rayos) CorticosteroidCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 2/27/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - February 27, 2019 Category: Rheumatology Source Type: news

New research insights hold promise for kids with DMD
(Children's National Health System) Prednisone, the current standard of care used to treat kids with Duchenne muscular dystrophy (DMD), reduces chronic inflammation but has harsh side effects. Eplerenone, a heart failure drug, is used in older patients to treat cardiomyopathy, a leading cause of mortality for people with DMD. A new medicine under development appears to combine the beneficial effects of these drugs for the heart and muscle while also showing improved safety in experimental models. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2019 Category: International Medicine & Public Health Source Type: news

Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis Thymectomy Improves Outcomes in Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone improves outcomes in patients with non-thymomatous myasthenia gravis (MG), compared with prednisone alone, according to results from the two-year extension of the MGTX randomized trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 6, 2019 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Thymectomy & #43; PDN Beneficial for Non-Thymomatous Myasthenia Gravis
WEDNESDAY, Jan. 30, 2019 -- For patients with non-thymomatous myasthenia gravis, thymectomy plus prednisone confers benefits versus prednisone alone at five years, according to a study published online Jan. 25 in The Lancet Neurology. Gil I. Wolfe,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 30, 2019 Category: Pharmaceuticals Source Type: news

ASH: A & #43;CHP Bests CHOP for Peripheral T-Cell Lymphoma
WEDNESDAY, Dec. 5, 2018 -- For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Adcetris (brentuximab vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.--(BUSINESS WIRE)--Nov. 16, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for Adcetris (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2018 Category: Drugs & Pharmacology Source Type: news

Corticosteroids are linked to an increased risk of irregular heart beat
(Natural News) Taking corticosteroids, such as prednisone, can increase your risk of suffering from irregular heartbeats, making you more likely to suffer from a heart condition, according to a study published in the Archives of Internal Medicine. Corticosteroids are naturally occurring hormones with a wide array of functions, including managing your stress response and regulating... (Source: NaturalNews.com)
Source: NaturalNews.com - November 16, 2018 Category: Consumer Health News Source Type: news

Prednisone Cuts Risk of Dangerous Immune-System Rebound During HIV-TB Treatment Prednisone Cuts Risk of Dangerous Immune-System Rebound During HIV-TB Treatment
Giving low-dose prednisone soon after initiation of HIV therapy to people who are both infected with tuberculosis and have very low CD4 counts can prevent their immune system from dangerously rebounding against the TB infection, doctors report.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 16, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Medical News Today: What is the difference between methylprednisolone and prednisone?
Methylprednisolone and prednisone are medications that can treat certain health conditions, such as rheumatoid arthritis, by reducing inflammation in the body. Learn about the differences between these corticosteroids here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 31, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Investigational steroid mirrors prednisone's benefits while taming its side effects
(Children's National Health System) A head-to-head trial comparing the decades-old steroid, prednisone, and a promising new steroid, vamorolone, finds both act on the same key set of genetic pathways involved in controlling inflammation, indicates a new study led by Children's National Health System researchers. However, the study suggests the new investigational steroid doesn't activate several additional pathways involved in prednisone's bevy of undesirable side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 20, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: How to deal with prednisone withdrawal
Prednisone is a drug that contains synthetic cortisol. When a person takes prednisone, the body stops making enough cortisol on its own. This can lead to withdrawal symptoms when the person stops taking the medication or reduces their dose too quickly. Here, learn more about the symptoms and how to prevent them. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 20, 2018 Category: Consumer Health News Tags: Pharmacy / Pharmacist Source Type: news

Deadly Respiratory Distress Mimic
Medic 534, staffed by a paramedic and EMT, is dispatched to a nursing home for a 78-year-old female in respiratory distress. On arrival, the crew finds the patient in a chair accompanied by two nurses and the administrator on call. The patient is in obvious distress showing fatigue and an increased work of breathing. She is alert to voice, but diaphoretic, lethargic, and unable to speak due to rapid, shallow breathing. A nurse is administering a nebulizer containing 3 mL of albuterol sulfate/ipratropium. A second nurse states that the patient has been in increasing distress for the last 45 minutes. The nurse also says that...
Source: JEMS Patient Care - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Patient Care Source Type: news

Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of av...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news